Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery

The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is effective in maintaining blood sugar control in patients with type 2 diabetes (T2D).

The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) and the need for continuous intravenous insulin infusion (CII) in the intensive care unit (ICU) in patients with type 2 diabetes (T2D) undergoing coronary artery bypass graft (CABG) surgery. In addition, the study seeks to determine whether treatment with sitagliptin is effective in maintaining glycemic control and in preventing the need for subcutaneous (SC) insulin therapy in patients with T2D during the transition from intensive care unit (ICU) to regular floor in cardiac surgery patients with T2D.

Inclusion Criteria:

• The ability to provide informed consent
• Ages 18 to 80 years old
• Male or female
• Scheduled to undergo cardiac surgery
• Type 2 Diabetes treated with diet, oral agents,

Exclusion Criteria:

• Severely impaired kidney function (glomeruler filtration rate (GFR ) less than 30 ml/min)
• Clinically significant liver failure
• Imminent risk of death (brain death or cardiac standstill)
• Gastrointestinal obstruction or adynamic ileus
• Expected to require gastrointestinal suction
• Clinically relevant pancreatic or gallbladder disease
• Using oral or injectable corticosteroid
• Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
• Female subjects are pregnant or breast feeding at time of enrollment into the study